Understand the source comparison
Selank Amidate vs Lexapro Mechanism: Full Comparison
Primary Mechanism GABA-A receptor subunit upregulation (α2/α3) + enkephalin degradation inhibition Selective serotonin reuptake inhibitor (SERT antagonist, Ki = 0.8 nM) Fundamentally different neurotransmitter systems. GABAergic stabilization vs serotonergic r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- GABA-A receptor subunit upregulation (α2/α3) + enkephalin degradation inhibition
- Selective serotonin reuptake inhibitor (SERT antagonist, Ki = 0.8 nM)
- Fundamentally different neurotransmitter systems. GABAergic stabilization vs serotonergic reuptake blockade
- Onset of Anxiolytic Effect
- 30–60 minutes (immediate gene expression modulation)
- 2–4 weeks (requires autoreceptor desensitization)
- Selank provides rapid relief; Lexapro requires patience through adaptation period
- Receptor Tolerance
- No downregulation observed in chronic use studies
- Postsynaptic receptor downregulation (5-HT2A/2C) after weeks
- Selank avoids tolerance development that defines chronic SSRI use
- Discontinuation Syndrome
- None. Can stop abruptly without withdrawal
- Common. SSRI discontinuation syndrome in 20–50% of patients
- Selank's lack of receptor dependence eliminates discontinuation risk
- Dosing Frequency
- Intermittent or daily as needed (no cumulative requirement)
- Daily continuous dosing required (missed doses reduce efficacy)
- Selank allows flexible use; Lexapro requires strict adherence
- Primary Side Effects
- Minimal. Occasional nasal irritation (intranasal route)
- Nausea (23%), sexual dysfunction (30–40%), insomnia (15%), weight gain
- Selank's peptide structure avoids monoamine-related side effects
- Half-Life
- ~25 minutes (plasma), 4–6 hours (neurochemical effect)
- 27–32 hours (allows once-daily dosing)
- Short pharmacokinetic half-life but sustained pharmacodynamic effect for selank
- Regulatory Status
- Research peptide (not FDA-approved for clinical use)
- FDA-approved for major depressive disorder and generalized anxiety disorder
- Lexapro has regulatory approval; selank requires informed research use